Dr. Jose De La Cerda III, MD

Dr. De La Cerda practices at Urology Partners of North Texas in Arlington, Texas.

Dr. De La Cerda's NPI, 1881038412, was assigned on April 25, 2013. Dr. De La Cerda graduated from Joe R. & Teresa Lozano Long School of Medicine in 2013. Dr. De La Cerda holds Texas license R5996.

Dr. De La Cerda's primary practice is Urology Partners of North Texas, at 5001 S Cooper St, Arlington, TX 76017 in Tarrant County. The practice phone is (866) 367-8768.

Dr. De La Cerda's primary practice is Urology Partners of North Texas in Arlington, Texas. Dr. De La Cerda is also affiliated with Methodist Hospital. The medical group on file is Urology Partners of North Texas. Dmand AI also links Dr. De La Cerda to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De La Cerda practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. De La Cerda's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. De La Cerda is board certified in urology by the American Board of Urology. Dr. De La Cerda is licensed in Texas.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, kidney stone disease, prostate cancer and prostate inflammation or infection among the conditions Dr. De La Cerda treats.

CMS data shows 3,984 Medicare services from Dr. De La Cerda across 29 procedure codes in 2024, for 567 Medicare patients. Medicare paid $151,549 for them.

CMS counts 567 Medicare patients who saw Dr. De La Cerda in 2024. The largest group is 75 to 84, with 226 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. De La Cerda's median patient age at 72, with 21% women.

In 2024, Dr. De La Cerda wrote 5,040 Medicare Part D claims for 1,218 patients. 81% of them were for generic drugs. CMS names the drug for 4,930 of them, across 43 drugs with 11 or more claims each, at $5,802,399 in total drug cost. In 2023, CMS named 4,446 claims across 38 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. De La Cerda for performance year 2024, reported as part of a group. Dr. De La Cerda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. De La Cerda, published from 2023 to 2025. 2025 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Phenylurea Compounds and Prostatic Neoplasms. Dr. De La Cerda has published most often in Target Oncol. Dr. De La Cerda's most frequent co-authors are Laurence H. Belkoff, DO, Lawrence A. Gervasi, MD and Ronald F. Tutrone, MD.

Dmand AI links Dr. De La Cerda to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Neoplasm Metastasis and Neoplastic Processes. Open Payments lists research payments to Dr. De La Cerda that name 1 trial.

CMS Open Payments shows 654 general payments to Dr. De La Cerda from 41 drug and device companies from 2018 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Janssen Pharmaceuticals, Inc paid the most, $165,339. It also lists 4 research payments totaling $9,248 from 2022 to 2025, naming 1 clinical trial.

Dr. De La Cerda graduated from Joe R. & Teresa Lozano Long School of Medicine in 2013.

Dr. De La Cerda is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.